Deciphera Pharmaceuticals, a subsidiary of Ono Pharmaceutical, has officially halted the development of its early-stage cancer drug DCC-3084, a pan-RAF inhibitor, due to strategic reasons not related to safety or efficacy. This decision impacts an ongoing open-label phase 1/2 study involving 29 patients with advanced solid tumors. Following Ono’s $2.4bn acquisition of Deciphera in 2024, which included the approved drugs Qinlock and Romvirza, the company remains committed to its pipeline. Promising candidates such as the BTK inhibitor tirabrutinib and antisense oligonucleotide sapablursen continue to advance through clinical trials.
